PLS Natural History Research

To know whether a treatment works, you first have to know what the disease does on its own. For PLS, that question — what does untreated disease look like, measured precisely, over years? — has taken decades to answer properly. The challenge is not just that PLS is rare. It is that PLS progresses slowly enough that distinguishing a genuine treatment effect from natural fluctuation requires either large cohorts, long follow-up, or objective markers sensitive enough to detect small changes. Natural history research is the foundation that makes any of that possible.

Why natural history is hard in PLS

In ALS, natural history is tractable if grim: most patients decline rapidly, and clinical endpoints are reachable within 12 to 18 months. PLS operates on a different timescale. Patients live for decades. Functional decline, when measured with standard rating scales, averages roughly 1.6 to 2 points per year on the ALSFRS-R — a scale that runs to 48. At that pace, detecting a 30% slowing of progression in a randomized trial would require years of follow-up or hundreds of patients, neither of which is easily achievable when you are working with a disease affecting fewer than 3,000 Americans.

This is why natural history research in PLS is not a preliminary step — it is an ongoing necessity. Every generation of natural history data refines the progression benchmarks, validates new outcome measures, and identifies biological markers that could eventually serve as sensitive endpoints in trials. The story of PLS natural history research is, at its core, the story of a field working to make itself trial-ready.

Where the evidence comes from

The foundation was laid before the current era of PLS research. In 1992, Pringle and colleagues at the National Hospital for Neurology and Neurosurgery in London made a case — based on systematic clinical and pathological review — that PLS was a discrete entity, not simply a variant of ALS. That distinction mattered: it created the clinical category that natural history research would spend the next three decades characterizing.

The first large, prospective, North American natural history data came from Gordon and colleagues in 2006, working through the Northeast ALS Consortium (NEALS). Drawing on 15 years of registry data and approximately 250 PLS patients, they documented an average functional decline of 1.6 ALSFRS-R points per year — a benchmark that every subsequent study has compared itself to. They also confirmed that survival in PLS was markedly better than ALS, with patients living for years to decades after diagnosis. This study became the reference standard: if you look at any PLS paper published after 2006, there is a near-certain chance it cites Gordon.

Three years later, Floeter and Mills at the NIH added a methodological dimension the field had lacked. Where Gordon's work was grounded in clinical rating scales, Floeter brought transcranial magnetic stimulation (TMS) to the problem — measuring cortical excitability directly as a neurophysiological index of upper motor neuron function. The finding that TMS measures correlated with clinical progression was significant: it showed that PLS could be tracked with objective neurophysiological tools, not just patient-reported function scores. This multimodal approach pointed toward the biomarker research that would accelerate a decade later.

By 2020, the field had a new anchor: the PLS consensus diagnostic criteria, developed by an international panel and published jointly. Before these criteria, natural history cohorts were difficult to compare across centers because researchers used different definitions of "probable" and "definite" PLS. The consensus criteria formalized what the community had been converging on: probable PLS requires absence of lower motor neuron signs for at least two years, and definite PLS requires four years. This standardization made cross-cohort comparison — essential for pooling natural history data — finally tractable.

With those criteria in place, the next wave of prospective studies was better positioned to build comparable datasets. The PLS Natural History Study (PNHS), funded by the CDC and running at Mayo Clinic and Johns Hopkins, is the most methodologically rigorous prospective PLS study yet conducted. It enrolled 76 participants with confirmed or probable PLS and followed them with serial PLSFRS measurements, biospecimen collection, and serum neurofilament light chain (NfL) sampling. The results, published in Annals of Neurology in September 2025, documented an average PLSFRS decline of 0.33 points per month — and, crucially, found that baseline NfL level significantly predicted how fast individual patients would decline over the following year (p = 0.001). That finding connects the natural history and biomarker agendas in a single study.

Two major synthesis efforts in 2025 consolidated what the field had learned. The Scirocco review from Mayo Clinic took explicit aim at trial readiness — mapping the current state of natural history knowledge against what a treatment trial would require, and identifying the PLSFRS and NfL as the most promising outcome measure and stratification biomarker, respectively. It also flagged something that earlier cohort work had not fully captured: neuroimaging now shows that PLS involves extra-motor pathology in frontotemporal, cerebellar, thalamic, and subcortical regions, challenging the historical framing of PLS as a "pure upper motor neuron" disease. That complication matters for trial design — if the disease is broader than the corticospinal tract, outcome measures focused purely on motor function may miss part of what is happening.

Independent European validation came from the Netherlands natural history cohort, which prospectively followed a national PLS population and assessed the 2020 consensus criteria against real-world clinical data. The Dutch findings were broadly consistent with North American benchmarks on rate of decline and survival — a cross-national replication that strengthens confidence in the generalizability of the core natural history numbers.

What we know — and what we don't

Across multiple independent cohorts — American, British, Dutch — the core findings hold. PLS progresses slowly. Functional decline averages 1.6 to 2 ALSFRS-R points per year. Survival from symptom onset is measured in decades: the most precise current estimate, 23.1 years from onset with a median age at death of 79.5 years, puts PLS commensurate with near-normal life expectancy. The great majority of PLS patients never require gastrostomy or ventilator support, with disability concentrated in gait and mobility rather than respiratory or bulbar function.

What the data does not resolve is individual variation. Population averages are useful for counseling; they are not predictions for any single patient. Approximately 23% of presentations that initially meet PLS criteria eventually develop lower motor neuron signs and receive an ALS diagnosis — which is why the 4-year threshold for "definite PLS" exists, and why patients early in their disease live with genuine prognostic uncertainty for years. The PNHS's finding that NfL predicts individual trajectory is the most promising development for personalizing prognosis, but it has not yet translated into clinical practice.

The honest gap in the natural history literature is this: almost everything we know comes from retrospective or cross-sectional data. The PNHS is the first genuinely prospective multicenter study, and its cohort of 76 patients — while the best we have — is still small by the standards of any clinical science where you want robust subgroup analyses or stratified modeling. The next generation of natural history research will need larger prospective cohorts, integrated biomarker measurement, and standardized outcome measures applied consistently across centers. The infrastructure being built by the PNHS is the direct path to that goal.

Why it matters for you

If you have received a PLS diagnosis, the natural history literature is what supports the core message your neurologist should be giving you: PLS is not ALS. The slow-progression story is real, it holds up across multiple independent datasets, and it should anchor how you think about long-term planning. The prognosis page translates this evidence into what it means practically. The clinical trials page explains how to participate in the research that will eventually produce a treatment — because every person who enrolls in the PNHS and future studies is contributing to the natural history data that makes a treatment trial possible.

Individual studies in this section

Full details on each study, including methods, findings, and context: